TD Cowen keeps USD 17 target for Sarepta Therapeutics stock

Published on 10/27/2026 at 13:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TD Cowen keeps its USD 17 target on October 21, 2026. Sarepta Therapeutics stock costs EUR 16.18 on October 27, 2026 at Lang & Schwarz.

Three dates shape the setup

TD Cowen maintained a USD 17.00 target on October 21, 2026.
Second-quarter revenue was USD 401.25 million versus USD 611.09 million a year earlier.
Sarepta Therapeutics stock was trading at EUR 16.18 at 1:11 p.m. CET at Lang & Schwarz on October 27, 2026.

SRPT, US8036071004, Illustration mit AI erstellt.

Sarepta Therapeutics (ISIN US8036071004) was trading at EUR 16.18 at Lang & Schwarz on October 27, 2026, at 1:11 p.m. CET. Markets Insider reported on October 21, 2026, that TD Cowen maintained a Hold rating and a USD 17.00 price target.

Target holds at USD 17

The analyst view follows Sarepta's second-quarter report, which showed revenue of USD 401.25 million for the quarter ended June 30, 2026, versus USD 611.09 million a year earlier. The company also reported a GAAP net loss of USD 4.89 million, compared with a GAAP net profit of USD 196.89 million in the prior-year quarter, according to Markets Insider.

Three dates shape the pipeline

On August 5, 2026, Sarepta announced its second-quarter results and recent corporate developments, with the revenue and earnings figures reported above, according to the company's investor-relations page. On October 14, 2026, the company presented SRP-1003 preclinical data showing 80 percent knockdown of pathogenic DMPK RNA, according to Investing.com. On October 22, 2026, Sarepta announced that it would report third-quarter results after the Nasdaq close on November 5, 2026, according to Yahoo Finance.

What does the target imply?

TD Cowen's USD 17.00 target sits alongside a mixed operating picture: second-quarter revenue was USD 401.25 million, while the company reported a USD 4.89 million GAAP loss. The November 5 results date will give investors a new reference point for product demand and the development pipeline.

Market value and next date

Sarepta is listed on the Nasdaq under the ticker SRPT. Its market capitalization was USD 1.9 billion as of October 26, 2026, and its 52-week range was USD 14.68 to USD 24.68. The next scheduled reporting date is November 5, 2026.

Stock trades ahead of results

The stock price gives the November event added importance because the current euro quotation sits within the lower half of the reported 52-week US-dollar range. The coming report will put fresh revenue and pipeline information against the USD 17.00 TD Cowen target.

The further course of trading is shown by the continuously updated real-time quote of Sarepta Therapeutics stock.